Clay B. Siegall, Ph.D.
President, Chief Executive Officer and Chairman of the Board
Seattle Genetics, Inc.
In 1998, Dr. Siegall co-founded Seattle Genetics and is the company’s President, CEO and Chairman of the Board. A scientist by training, Dr. Siegall built Seattle Genetics on a foundation of scientific innovation, rigorous research and drug development practices as well as a passion for helping patients. He has guided the company to its current leadership position in the field of antibody-drug conjugates (ADCs) and in the 2011 FDA approval of our first ADC product, ADCETRIS® (brentuximab vedotin). Under a collaboration with Takeda Pharmaceutical Company, ADCETRIS is now a global brand that is approved in 71 countries. Seattle Genetics is the largest biotech based in the Pacific Northwest and an emerging global, multi-product oncology company with three programs for solid tumors in late-stage development.
Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. He holds 15 patents and is an author on more than 70 publications. He serves as a member of the board of directors of Ultragenyx Pharmaceutical, Alder BioPharmaceuticals and Washington Roundtable. Dr. Siegall received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.
Claire's Restaurant and Lounge 301 Main Street Edmonds, WA 98020